Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

PT-141 Research History: Melanotan II to Modern Lab Use | Palmetto Peptides

History of PT-141 Research Peptide: From Melanotan II Discoveries to Modern Laboratory Applications Research Notice: This article covers research on Melanotan II (MT-2) research peptide and PT-141 research peptide — available from Palmetto Peptides for laborat

By Recovery & Performance Peptides Editorial Team

History of PT-141 Research Peptide: From Melanotan II Discoveries to Modern Laboratory Applications

Research Notice: This article covers research on Melanotan II (MT-2) research peptide and PT-141 research peptide — available from Palmetto Peptides for laboratory use only.

Last Updated: January 15, 2025

Research Use Only Disclaimer: PT-141 (Bremelanotide) is sold exclusively for laboratory and preclinical research purposes. It is not intended for human or veterinary use, consumption, or self-administration. All information on this page is provided for scientific and educational reference only. Researchers must comply with all applicable federal, state, and local regulations governing the use of research peptides.

The story of PT-141 is one of the more compelling examples of how a serendipitous discovery in one area of peptide science can open an entirely unexpected research pathway. Understanding its history gives laboratory scientists important context for interpreting preclinical data, designing experiments, and recognizing why this compound occupies a unique position among melanocortin system research tools.

Last Updated: April 6, 2026 | Reading Time: Approximately 10 minutes | Author: Palmetto Peptides Research Team

Quick Answer

The Melanocortin System: Setting the Stage

Before PT-141 had a name, researchers were already deeply interested in the melanocortin system, a network of receptors (MC1R through MC5R) activated by peptide ligands derived from proopiomelanocortin (POMC). These receptors regulate a remarkably broad range of physiological processes in animal models, including pigmentation, energy balance, inflammation, and autonomic function.

The five melanocortin receptor subtypes each show distinct tissue expression patterns and pharmacological profiles. MC1R is predominantly expressed in melanocytes and plays a central role in pigmentation signaling. MC3R and MC4R are expressed in the central nervous system and have been the subject of extensive preclinical research related to energy homeostasis and autonomic pathways. Understanding how selective agonism or antagonism at each receptor subtype affects in vitro and in vivo outcomes became a major goal for peptide chemists through the 1980s and 1990s.

Alpha-MSH and the Early Melanocortin Peptide Research Era

The natural melanocortin peptides, particularly alpha-melanocyte-stimulating hormone (alpha-MSH), were characterized decades before PT-141 entered the research landscape. Alpha-MSH is a 13-amino acid peptide derived from POMC cleavage, and early research demonstrated its potent activation of melanocortin receptors in animal tissue preparations.

A key challenge with alpha-MSH in research settings was its short half-life. Like many endogenous peptides, it was rapidly degraded by enzymatic activity in biological samples. This pharmacokinetic limitation prompted peptide chemists to explore structural modifications that could extend stability without eliminating receptor binding affinity.

This line of inquiry gave rise to a generation of synthetic melanocortin analogs that would eventually lead to the Melanotan compounds and, downstream, to PT-141 itself.

The University of Arizona and the Melanotan Research Program

Much of the foundational work that produced PT-141 traces back to a research program at the University of Arizona, where investigators were exploring the pharmacology of melanocortin peptides in the context of pigmentation biology. The research group, led in part by Dr. Victor Hruby, had longstanding expertise in peptide synthesis and structure-activity relationship (SAR) analysis.

The goal of the early Melanotan research program was to develop alpha-MSH analogs with improved receptor binding characteristics and longer metabolic stability compared to the native peptide. Melanotan I (afamelanotide) was one of the early compounds to emerge from this program. It incorporated structural modifications, including a lactam bridge and substitutions at key residues, that enhanced metabolic resistance and melanocortin receptor affinity.

Melanotan II (MT-II) followed as a further-modified cyclic heptapeptide. Its structural compactness gave it enhanced potency at melanocortin receptors, and it became a widely used tool compound in preclinical melanocortin system research. MT-II's pharmacology proved to be notably nonselective across receptor subtypes, which made it a useful probe for exploring the broader melanocortin system but also complicated interpretation of subtype-specific effects.

From Melanotan II to PT-141: The Structural Transition

The transition from MT-II to PT-141 represents a meaningful chapter in the SAR history of melanocortin peptides. During preclinical and early phase research with Melanotan compounds, researchers noted that some observed biological signals in animal models appeared to involve receptor pathways distinct from those driving pigmentation responses.

This observation prompted further structural modification work. PT-141, also known by its INN Bremelanotide, is structurally derived from MT-II. The primary chemical distinction involves the removal of the MT-II N-terminal acetyl group combined with other modifications resulting in a linear, then cyclized peptide with altered receptor binding kinetics relative to its parent compound.

The amino acid sequence of PT-141 is: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH (variations in reporting exist in the literature depending on specific synthesis protocols). Its cyclic lactam structure contributes to conformational rigidity that influences receptor binding selectivity and metabolic stability compared to linear melanocortin peptides.

PT-141 in Preclinical Research: A Timeline Overview

The following table summarizes key milestones in PT-141 research history from a scientific literature perspective:

Late 1980s

Alpha-MSH analog synthesis

Foundational SAR work on melanocortin peptides at U of AZ

Early 1990s

Melanotan I and II synthesis

MT-I and MT-II characterized as potent, stable melanocortin agonists

Mid 1990s

MT-II preclinical studies

Broad receptor pharmacology explored in animal models

Late 1990s

PT-141 structural derivation

Bremelanotide synthesized as MT-II structural derivative

Early 2000s

Melanocortin receptor selectivity studies

MC3R/MC4R pathway research intensifies using PT-141 as tool compound

2010s

Continued preclinical investigation

PT-141 used in receptor binding assays and CNS receptor mapping studies

Receptor Pharmacology Research: What the Preclinical Literature Covers

One reason PT-141 has remained a relevant research compound over decades is its pharmacological profile at melanocortin receptor subtypes. Unlike MT-II, which shows potent activity across multiple receptor subtypes, PT-141 has been studied for its relative selectivity profile at MC3R and MC4R in in vitro assay systems.

MC4R, in particular, has attracted significant research interest due to its expression in hypothalamic and limbic brain regions in animal models. Preclinical radioligand binding studies and in vitro functional assays have used PT-141 as a reference compound to characterize the pharmacological properties of the MC4R binding site.

This receptor-level research does not support any specific clinical conclusions. Rather, it has helped build a more detailed picture of melanocortin receptor pharmacology, ligand-receptor interaction kinetics, and the structural requirements for receptor activation in cell-free and cell-based systems.

PT-141 as a Reference Compound in Melanocortin Research

In modern laboratory applications, PT-141 (Bremelanotide) continues to serve several functions as a research tool compound:

Receptor Binding Reference: PT-141 is used in competitive radioligand binding assays to characterize the affinity and kinetics of novel melanocortin receptor ligands. Its well-characterized binding profile at MC3R and MC4R makes it a useful comparator in binding competition experiments.

In Vitro Cell-Based Assays: Researchers use PT-141 to activate melanocortin receptors in transfected cell lines, measuring downstream second messenger signaling (cyclic AMP, beta-arrestin recruitment) to study receptor activation pathways.

SAR Studies: PT-141's structure provides a scaffold for comparative SAR research, allowing chemists to explore how structural modifications to the cyclic lactam template affect receptor selectivity and binding kinetics.

Comparative Pharmacology: Because both MT-II and PT-141 are available as research-grade standards, they are frequently used as paired comparison compounds in assays designed to investigate structure-activity differences within the cyclic melanocortin peptide scaffold.

The Peptide Chemistry Context: Why Structure Shapes Research Value

To understand why PT-141's history matters to the working laboratory scientist, it helps to appreciate what the structural evolution from alpha-MSH to MT-II to PT-141 actually changed at the molecular level.

Alpha-MSH is a linear tridecapeptide. Its flexibility in solution means it can adopt multiple conformations when approaching a receptor binding site, which affects both potency and selectivity. Synthetic analogs that introduce conformational constraints, such as cyclic lactam bridges or D-amino acid substitutions, restrict the peptide's conformational space and often improve receptor binding potency and selectivity.

PT-141's cyclic structure is a direct product of this strategy. The lactam bridge between the epsilon-amino group of the lysine residue and the carboxyl group of the aspartate residue enforces a specific backbone geometry. The incorporation of D-phenylalanine at a key position further modifies the peptide's binding orientation. The net result is a compound with distinct receptor pharmacology compared to both alpha-MSH and MT-II.

For researchers designing binding assays or cell-based functional studies, this structural context is directly relevant to experimental interpretation.

Regulatory and Research Compliance Context

It is important for researchers sourcing PT-141 to understand where it sits in the regulatory landscape. PT-141 (Bremelanotide) is not approved as an active pharmaceutical ingredient (API) for any research use without appropriate institutional oversight in the United States. Research institutions conducting experiments with PT-141 must maintain appropriate documentation and comply with institutional policies governing the use of research chemicals.

Palmetto Peptides supplies PT-141 exclusively as a research peptide for use in qualified laboratory settings. All products come with a Certificate of Analysis (COA) confirming purity and identity. Purchasers are responsible for ensuring that their use of this compound complies with all applicable regulations.

See our article on Legal and Regulatory Considerations for Buying PT-141 and Other Research Peptides in the US for a full discussion of the compliance framework.

Related Research Resources in This Cluster

Palmetto Peptides Guide to the Research Peptide PT-141 (Bremelanotide)

PT-141 Chemical Structure, Sequence, and Molecular Properties for Research Use

PT-141 Mechanism of Action as a Melanocortin Receptor Agonist in Preclinical Research

PT-141 vs Melanotan II: Comparative Analysis for Research Peptide Applications

Ensuring Purity and Quality When Purchasing PT-141 Research Peptides: What to Look For

PT-141 Structure-Activity Relationships: How Molecular Modifications Affect Melanocortin Receptor Research Outcomes

Frequently Asked Questions

Q: What is the origin of PT-141 as a research compound? PT-141 (Bremelanotide) was derived from Melanotan II (MT-II), a cyclic melanocortin peptide analog originally developed at the University of Arizona. Structural modifications to MT-II produced PT-141, which has a distinct receptor pharmacology profile used in preclinical melanocortin receptor research.

Q: How does PT-141 differ structurally from Melanotan II? PT-141 is structurally derived from MT-II with modifications affecting N-terminal chemistry and overall receptor binding profile. Both compounds share a cyclic lactam scaffold, but distinct structural features result in different receptor selectivity at melanocortin receptor subtypes in vitro.

Q: What melanocortin receptors does PT-141 interact with in research settings? In preclinical research, PT-141 has been characterized primarily as an agonist at MC3R and MC4R subtypes. It has been used in radioligand binding assays and cell-based functional studies to probe these receptor subtypes in vitro.

Q: Is PT-141 approved for human use? PT-141 as supplied by Palmetto Peptides is a research-grade compound intended exclusively for laboratory and preclinical use. It is not sold or intended for human or veterinary administration.

Q: Why is the history of PT-141 relevant to laboratory researchers? Understanding PT-141's developmental history from alpha-MSH analogs through Melanotan I and II to Bremelanotide provides essential context for interpreting its receptor pharmacology, designing appropriate control experiments, and placing published preclinical data in its proper scientific framework.

Citations

Hadley ME, Dorr RT. "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization." Peptides. 2006;27(4):921-930. PubMed

Hruby VJ, Lu D, Sharma SD, et al. "Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5,D-Phe7,Lys10] alpha-MSH-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors." Journal of Medicinal Chemistry. 1995;38(18):3454-3461.

Wikberg JE. "Melanocortin receptors: new opportunities in drug discovery." Expert Opinion on Therapeutic Patents. 2001;11(1):61-76.

Cone RD. "Studies on the physiological functions of the melanocortin system." Endocrine Reviews. 2006;27(7):736-749. PubMed

Dorr RT, Lines R, Levine N, et al. "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study." Life Sciences. 1996;58(20):1777-1784.

Author: Palmetto Peptides Research Team

This article is intended for educational and scientific reference purposes only. PT-141 is a research peptide sold exclusively for laboratory use. It is not intended for human or veterinary use, diagnosis, treatment, or prevention of any condition. Always consult institutional guidelines and applicable regulations before conducting research with this compound.

Related research: MT-2 complete research guide, and MT-2 melanocortin receptor mechanism.

See Also: Complete PT-141 Research Guide

Related Research

Browse related peptide research and products at Palmetto Peptides.

Related Peptide Research

PT-141 Research Guide

MT-II Mechanism of Action

Top 10 Research Peptides of the Future

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

PT-141 50s Age Protocol — Dosing & Safety | Real Peptides

Most PT-141 protocols ignore a critical variable. Age-related endothelial sensitivity shifts dosing requirements substantially after 50. Starting at therapeutic doses designed for younger adults amplifies cardiovascular side effects (transient hypertension, facial flushing, tachycardia) without improving outcomes. A 2019 analysis published in the Journal of Sexual Medicine found that patients over 50 experienced 40% higher rates of vasomotor side effects at standard 1.75mg doses compared to patients under 40, despite equivalent efficacy at lower doses. The mechanism is straightforward: declining nitric oxide bioavailability and reduced arterial compliance mean melanocortin receptor activation in vascular smooth muscle produces exaggerated pressor responses. We've worked with researchers across multiple 503B facilities refining peptide reconstitution and dosing protocols for age-stratified populations. The gap between doing PT-141 right in your 50s and doing it wrong comes down to three factors most guides never address: pre-existing endothelial dysfunction screening, dose titration timing relative to meal intake, and subcutaneous versus intranasal administration trade-offs in patients with compromised nasal mucosa. What is PT-141 and why does age change the protocol? PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist that induces sexual arousal through central and peripheral MC3R and MC4R activation. Distinct from PDE5 inhibitors like sildenafil, which work …
STORAGE

Reconstitution, Storage, and Handling Protocols

Lyophilised PT-141 must be stored at −20°C before reconstitution. Once mixed with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Any temperature excursion above 8°C causes irreversible peptide degradation that neither appearance nor home potency testing can detect. Vyleesi autoinjectors are shipped refrigerated and must remain at 2–8°C until use; they cannot be frozen or stored above 25°C for more than 24 hours. Reconstitution errors are the most common failure point we see. The correct technique: (1) Allow lyophilised vial to reach room temperature for 10–15 minutes. (2) Inject bacteriostatic water slowly down the inside wall of the vial, never directly onto the peptide powder. Direct injection denatures protein structure at the injection site. (3) Swirl gently. Do not shake. Shaking introduces air bubbles and mechanical shear stress that fragments peptide chains. (4) Allow to dissolve completely (2–5 minutes) before drawing first dose. (5) Never inject air into the vial while drawing solution. The resulting pressure differential pulls contaminants back through the needle on every subsequent draw. Dosing equivalence: Vyleesi delivers 1.75mg bremelanotide per autoinjector. Compounded PT-141 is typically supplied as 10mg lyophilised powder reconstituted with 2–5mL bacteriostatic water, yielding 2–5mg/mL concentration. A 1.75mg dose requires 0.35–0.875mL injection volume depending on reconstitution ratio. Most users find 0.5mL per dose (3.5mg/mL concentrati…
02

Question drills

Open a question for its connected answer.

01What If PT-141 Results After 2 Weeks Are Strong — Can I Increase Dose?+

Do not escalate dose based solely on early-phase response strength. The 1.75mg subcutaneous dose used in Phase 3 trials represents the therapeutic ceiling for most users. Higher doses increase nausea and flushing risk without proportional efficacy gains. Strong two-week results indicate favorable baseline receptor density, not a need for dose adjustment. Maintain the current dose and allow the melanocortin pathway to fully saturate over the subsequent 4–6 weeks. Our team has observed that users who aggressively titrate upward during week 2–3 experience side effect escalation without meaningful arousal enhancement beyond what the standard dose would have produced.

SOURCE / realpeptides.co ↗
02What If I Experience Severe Nausea After My First PT-141 Dose?+

Reduce the next dose to 1.0 mg and assess tolerance before escalating back to 1.75 mg. Nausea is dose-dependent. The RECONNECT trials found 28% nausea incidence at 1.0 mg vs 40% at 1.75 mg. Pretreatment with ondansetron 4 mg oral 30 minutes before PT-141 injection reduces nausea severity, but some patients report blunted arousal response when serotonin antagonists are co-administered. The mechanism isn't fully understood, but 5-HT3 blockade may interfere with downstream limbic signalling that PT-141 initiates. Try dose reduction first; add ondansetron only if nausea persists at lower doses.

SOURCE / realpeptides.co ↗
03What If You Need to Differentiate MC3R from MC4R Activation in a Mixed Cell Population?+

Use receptor-selective antagonists in competition assays. THIQ (MC4R-selective antagonist, Kᵢ ~10 nM at MC4R, >1 μM at MC3R). Pre-treat cells with 100 nM THIQ for 15 minutes, then dose with PT-141 and measure cAMP; if the response is abolished, the signal was MC4R-mediated. If cAMP elevation persists, the residual activity is MC3R-driven. This approach is essential when working with neuronal cultures or hypothalamic cell lines that co-express multiple melanocortin receptors.

SOURCE / realpeptides.co ↗
04What If My Reconstituted PT-141 Is Approaching the 28-Day Mark?+

Use it or discard it. Bacteriostatic water's antimicrobial efficacy and the peptide's chemical stability both decline sharply beyond 28 days. By day 30, even under ideal refrigeration, expect 10–15% potency loss from cumulative oxidation and hydrolysis, and microbial contamination risk rises significantly in multi-dose vials. Some research teams extend use to 35 days if the vial has been handled with strict aseptic technique and stored without temperature excursions, but this is a calculated risk. Pharmaceutical guidelines do not support use beyond 28 days post-reconstitution.

SOURCE / realpeptides.co ↗
05What If Nausea Occurs Within Minutes of Injection?+

Nausea onset within 30–60 minutes is expected in 40–50% of participants at 1.75mg doses. This is a pharmacological response to MC4R activation in the area postrema, not an allergic reaction. Pre-treatment with ondansetron 4mg orally 30 minutes before PT-141 administration reduces nausea incidence by approximately 30% without attenuating the compound's melanocortin activity. Ginger supplementation (1g extract) and remaining upright (avoiding recumbent positioning) for the first two hours post-dose also mitigate severity. If nausea persists beyond four hours or is accompanied by vomiting, that warrants clinical evaluation. Prolonged emesis can indicate dose-dependent toxicity or individual hypersensitivity.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

PT-141 Central Nervous System Sexual Arousal: Research Applications

PT-141 central nervous system sexual arousal is being studied in several contexts where traditional vascular treatments have failed or where the dysfunction is known to be centrally mediated. The FDA approved bremelanotide (Vyleesi) in 2019 specifically for acquired, generalized HSDD in premenopausal women. Making it the first melanocortin receptor agonist approved for a sexual dysfunction indication. That approval was based on the RECONNECT trials, which demonstrated statistically significant increases in sexual desire and decreases in distress related to low desire compared to placebo. Research applications extend beyond HSDD. Labs are investigating PT-141 central nervous system sexual arousal in the context of antidepressant-induced sexual dysfunction (AISD), which affects 40–65% of patients on selective serotonin reuptake inhibitors (SSRIs). SSRIs suppress dopamine and increase serotonin in ways that blunt reward signaling. The exact pathways PT-141 modulates through melanocortin receptor activation. A pilot study published in CNS Spectrums found that bremelanotide improved sexual desire in women experiencing SSRI-induced libido suppression, suggesting the melanocortin system can partially override serotonergic inhibition of arousal circuits. Another research focus: post-menopausal sexual dysfunction. Estrogen and testosterone replacement address some hormonal contributors to low libido, but many post-menopausal women report persistent low desire despite normalized hormone levels. That subset likely has a central arousal deficit that hormone replacement doesn't fully correct. Which is where PT-141 central nervous system sexual arousal becomes relevant. Ongoing trials are assessing whether melanocortin receptor agonists can restore desire in post-menopausal populations who don't respond to estradiol or transdermal testosterone. Real Peptides supplies research-grade PT-141 Bremelanotide and other peptides like Kisspeptin 10, which modulates gonadotropin-releasing hormone pathways involved in reproductive behavior, and Oxytocin, a neuropeptide that enhances pair bonding and genital sensation perception. Labs studying sexual arousal mechanisms often cross-reference melanocortin, kisspeptin, and oxytocin pathways because they converge in the hypothalamus and paraventricular nucleus. The same regions where PT-141 exerts its effects.

RESEARCH

The Role of Non-Standard Residues in Research Relevance

Two residues in PT-141's sequence deserve special attention because they were deliberately introduced to optimize the compound for research use: Norleucine (Nle) and D-Phenylalanine (D-Phe).

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles